@article{1c67ffd3d10c41a9a1bdad6677b71342,
title = "Extending the aspirin-free paradigm to patients with acute coronary syndrome: is it time to change guidelines?",
author = "Usman Baber and Roxana Mehran",
note = "Funding Information: U. Baber has received personal fees from Amgen, Boston Scientific and AstraZeneca. R. Mehran reports institutional research grants from Abbott Laboratories, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, OrbusNeich; consultant fees from Abbott Laboratories, Boston Scientific, CardiaWave, Chiesi, Janssen Scientific Affairs, Medscape/WebMD, Medtelligence (Janssen Scientific Affairs), Roivant Sciences, Sanofi, Siemens Medical Solutions; consultant fees paid to the institution from Abbott Laboratories, Bristol-Myers Squibb; advisory board, funding paid to the institution from Spectranetics/Philips/Volcano Corp; consultant (spouse) from Abiomed, The Medicines Company, Merck; Equity <1% from Claret Medical, Elixir Medical; DSMB Membership fees paid to the institution from Watermark Research Partners; consulting (no fee) from Idorsia Pharmaceuticals Ltd., Regeneron Pharmaceuticals; and is an Associate Editor for ACC, AMA.",
year = "2020",
doi = "10.4244/EIJV16I8A115",
language = "English",
volume = "16",
pages = "620--622",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "Europa Group",
number = "8",
}